PBAC accused of ‘lack of ambition’

Manufacturers of GLP-1 medications are stepping up pressure on the federal government to subsidise their products for weight loss  Sponsors of glucagon-like peptide-1 (GLP-1) medications are accusing the Pharmaceutical Benefits Advisory Committee (PBAC) of not taking obesity seriously, with the body flagging cost as a reason not to subsidise the treatments for weight loss.   The Australian Financial Review (AFR)